Serum Institute India | Clinical Trials Search

找到 13,055 条关于 “Serum Institute India”

需要更精确的结果？

可按分期、招募状态、国家、申办方、年龄和研究类型筛选。

高级筛选临床试验

PACTR202206719871582

Study to Compare Safety and Immunogenicity of Yellow Fever Vaccine of Serum Institute of India with with STAMARI

计划入组 1,824 人

PACTR202206910703861

Study on Yellow Fever Vaccine developed by Serum Institute of India Pvt. Ltd. for comparison of safety and immunogenicity with other vaccine (STAMARIL) In Healthy Infants

计划入组 2,216 人

A Study of Comparing Safety and Reactogenicity, of Lyophilized BCG Vaccine IP of Green Signal Bio Pharma Private Limited, India With BCG Vaccine of Serum Institute of India Limited in 120 Healthy Children.

计划入组 120 人 · 首次发布于 2010 年 11 月 30 日

Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants

计划入组 346 人 · 首次发布于 2014 年 12 月 4 日

Assess the Safety and Immunogenicity of PNEUMOSIL® Vaccine in Healthy Vietnamese Children, 6 Weeks to 24 Months of Age

计划入组 300 人 · 首次发布于 2021 年 12 月 1 日

PACTR201907754270299

Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL)

计划入组 660 人

The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks

计划入组 222 人 · 首次发布于 2019 年 4 月 30 日

Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants

计划入组 660 人 · 首次发布于 2019 年 4 月 1 日

Prevalence of Comorbidities in Patients Undergoing Oncosurgeries at Tertiary Cancer Institute in North India.

计划入组 150 人 · 首次发布于 2021 年 9 月 9 日

Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial

计划入组 2,332 人 · 首次发布于 2015 年 7 月 21 日

第 1 页，共 433 页